Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (Currently Amended) A compound of formula (I):



(I)

wherein:

Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl is ~~may be~~ optionally substituted on carbon by one or more groups selected from R^4;

~~One~~ one of $\mathbf{R^1}$ and $\mathbf{R^2}$ is hydrogen and the other is hydrogen or C_{1-4}alkyl; wherein R^1 and R^2 are optionally ~~may be~~ substituted on carbon by one or more groups selected from R^5;

$\mathbf{R^3}$ is selected from C_{1-4}alkyl, C_{1-4}alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein R^3 is ~~may be~~ independently optionally substituted on carbon by one or more groups selected from R^6; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen ~~may be~~ is optionally substituted by C_{1-4}alkyl;

$\mathbf{R^4}$ is selected from halo, carboxy and C_{1-4}alkyl;

$\mathbf{R^5}$ and $\mathbf{R^6}$ are independently selected from halo, C_{1-4}alkyl, C_{1-4}alkoxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, carbocyclyl, heterocyclyl, carbocyclyloxy, heterocyclyloxy and carbocyclylidenyl; wherein R^5 and R^6 ~~may be~~ are independently optionally substituted on carbon by one or more R^7; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen ~~may be~~ is optionally substituted by C_{1-4}alkyl;

$\mathbf{R^7}$ is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and *N*-methyl-*N*-ethylamino;

or a salt, solvate or pro-drug thereof.

2. (Original) A compound according to Claim 1 wherein Ring **A** is unsubstituted or is substituted by carboxy.

3. (Currently Amended) A ~~compounds~~ compound according to ~~any one of the preceding claims~~ Claim 1 wherein one of $\mathbf{R^1}$ and $\mathbf{R^2}$ is hydrogen and the other is hydrogen or C_{1-4}alkyl.

4. (Currently Amended) A compound according to ~~any one of the preceding claims~~ Claim 1 wherein $\mathbf{R^3}$ is selected from C_{1-4}alkoxy; wherein $\mathbf{R^3}$ ~~may be~~ is independently optionally substituted on carbon by one or more groups selected from $\mathbf{R^6}$.

5. (Currently Amended) A compound according to ~~any one of the preceding claims~~ Claim 1 wherein $\mathbf{R^3}$ is selected from 2-fluorobenzyloxy, 5-methylisoxazol-3-ylmethoxy and 2-thien-3-ylethoxy

6. (Original) A compound according to Claim 1 selected from:

2-methyl-4-isobutoxy-6-[*N*-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

2-methyl-4-(2-fluorophenylmethoxy)-6-[*N*-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

2-methyl-4-isobutoxy-6-[*N*-(5-carboxythiazol-2-yl)carbamoyl]benzofuran;

2-methyl-4-(5-methylisoxazol-3-ylmethoxy)-6-[*N*-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

4-(2-fluorophenylmethoxy)-6-[*N*-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

4-(5-methylisoxazol-3-ylmethoxy)-6-[*N*-(5-carboxypyridin-2-yl)carbamoyl]benzofuran;

2-methyl-4-(thien-2-ylethoxy)-6-[*N*-(5-carboxypyridin-2-yl)carbamoyl]benzofuran; and

2-methyl-4-isobutoxy-6-[*N*-(thiazol-2-yl)carbamoyl]benzofuran;

or a salt, solvate or pro-drug thereof.

7. (Original) A pharmaceutical composition comprising a compound according to any one of Claims 1 to 6, or a salt, pro-drug or solvate thereof, together with a pharmaceutically acceptable diluent or carrier.

8. (Currently Amended) A method of treating a disease mediated through glucokinase, comprising administering a compound according to any one of Claims 1 to 6 ~~for use in the preparation of a medicament for treatment of a disease mediated through GLK~~.

9. (Currently Amended) A process for preparing a compound of formula (I): ~~, as defined in Claim 1,~~



(I)

wherein:

Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl is optionally substituted on carbon by one or more groups selected from R^4;

one of $\mathbf{R^1}$ and $\mathbf{R^2}$ is hydrogen and the other is hydrogen or C_{1-4}alkyl; wherein R^1 and R^2 are optionally substituted on carbon by one or more groups selected from R^5;

$\mathbf{R^3}$ is selected from C_{1-4}alkyl, C_{1-4}alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein R^3 is independently optionally substituted on carbon by one or more groups selected from R^6; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C_{1-4}alkyl;

$\mathbf{R^4}$ is selected from halo, carboxy and C_{1-4}alkyl;

$\mathbf{R^5}$ and $\mathbf{R^6}$ are independently selected from halo, C_{1-4}alkyl, C_{1-4}alkoxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, carbocyclyl, heterocyclyl, carbocyclyloxy, heterocyclyloxy and carbocyclylidenyl; wherein R^5 and R^6 are independently optionally substituted on carbon by one or more R^7; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C_{1-4}alkyl;

R^7 is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and *N*-methyl-*N*-ethylamino

or a salt, solvate or pro-drug thereof, which process ~~(wherein variable groups are, unless otherwise specified, as defined in Claim 1)~~ comprises:

Process 1): reacting an acid of formula **(II)**:



(II)

or an activated derivative thereof; with a compound of formula **(III)**; or



(III)

Process 2) for compounds of formula **(I)** wherein R^4 is carboxy; deprotecting a compound of formula **(III)**:



(III)

wherein $R^xC(O)O$- is an ester group;

and optionally ~~thereafter if necessary or desirable~~:

i) converting a compound of the formula **(I)** into another compound of the formula **(I)**; ~~and/or~~

ii) removing any protecting groups; ~~and/or~~

iii) forming a salt, solvate or pro-drug thereof, or a combination thereof .

10. A compound of formula (III): ~~as defined in Claim 9~~



(III)

wherein:

$R^xC(O)O$- is an ester group;

Ring A is pyridin-2-yl or thiazol-2-yl; wherein said pyridin-2-yl or thiazol-2-yl is optionally substituted on carbon by one or more groups selected from R^4; and

one of $\mathbf{R^1}$ and $\mathbf{R^2}$ is hydrogen and the other is hydrogen or C_{1-4}alkyl; wherein R^1 and R^2 are optionally substituted on carbon by one or more groups selected from R^5;

$\mathbf{R^3}$ is selected from C_{1-4}alkyl, C_{1-4}alkoxy, carbocyclyl, heterocyclyl, carbocyclyloxy and heterocyclyloxy; wherein R^3 is independently optionally substituted on carbon by one or more groups selected from R^6; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C_{1-4}alkyl;

$\mathbf{R^4}$ is selected from halo, carboxy and C_{1-4}alkyl;

$\mathbf{R^5}$ and $\mathbf{R^6}$ are independently selected from halo, C_{1-4}alkyl, C_{1-4}alkoxy, *N*-(C_{1-4}alkyl)amino, *N,N*-(C_{1-4}alkyl)$_2$amino, carbocyclyl, heterocyclyl, carbocyclyloxy, heterocyclyloxy and carbocyclylidenyl; wherein R^5 and R^6 are independently optionally substituted on carbon by one or more R^7; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen is optionally substituted by C_{1-4}alkyl; and

$\mathbf{R^7}$ is selected from halo, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, ethylamino, dimethylamino, diethylamino and *N*-methyl-*N*-ethylamino.